Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer

Hope S. Rugo, MD
Published: Friday, Apr 07, 2017



Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

The final overall analysis of the phase II study of abemaciclib, a CDK4/6 inhibitor, showed an overall survival of about 22 months.

This trial suggests that abemaciclib has significant single-agent activity. Additionally, this agent may improve progression-free survival when combined with hormone therapy such as fulvestrant (Faslodex), says Rugo.
 
SELECTED
LANGUAGE


Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

The final overall analysis of the phase II study of abemaciclib, a CDK4/6 inhibitor, showed an overall survival of about 22 months.

This trial suggests that abemaciclib has significant single-agent activity. Additionally, this agent may improve progression-free survival when combined with hormone therapy such as fulvestrant (Faslodex), says Rugo.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x